The DOI matches its Crossref record.
Use and significance of anti-CCP autoantibodies in rheumatoid arthritis
Open accessAbstract
One of the most common autoimmune diseases is rheumatoid arthritis (RA), affecting 0.5–1% of the population. This systemic disease is marked by chronic inflammation of synovial joints, which leads to destruction of cartilage and bone and eventually to disability of the patient [1]. Though not directly life-threatening, RA severely affects the quality of life of a patient and also has major economic consequences for society. Therefore, every attempt should be made to prevent the erosive processes to occur. Currently, the classification of RA relies mainly on the criteria described by the American College of Rheumatology (ACR) [2]. These criteria, originally formulated 50 yr ago and last adjusted in 1987, are based mainly on clinical parameters. Since these parameters are often only sufficiently fulfilled when the damaging effects of the inflammatory process are already in progress, this set of criteria is not very suitable for the early diagnosis of RA [3]. The key to early recognition of autoimmunity lies within the humoral immune system. Since blood samples are taken from clinic-visiting (pre-)patients, screening for serological RA-indicators can be performed quite easily. In the ACR criteria for RA one serological marker is included: rheumatoid factor (RF). The RF autoantibody system, directed against the Fc part of immunoglobulin (Ig) G molecules, has had a central role in the diagnosis and prognosis of RA during recent decades [4] because RF can be detected in the majority of RA patients. However, it is becoming more and more clear that the presence of RF is not restricted to patients with RA, but that it can also be detected in subsets of patients suffering from other diseases and even in a percentage of healthy (especially elderly) individuals [5]. The resulting lack of specificity for RA can lead to confusion and unwanted treatment. The shortcomings of the RF test have kept the search for more specific RA markers alive. Most autoantibody systems described during recent decades have failed to mature into mainstream tests for RA because of low sensitivity, lack of specificity or technical inconvenience, as reviewed previously [6–8]. The only antibody system that combines good sensitivity with superior specificity for RA is that targeting citrullinated epitopes. This review will focus mainly on the diagnostic potential of the second-generation anti-cyclic citrullinated peptide (CCP) test (CCP2) for RA. Next, we will address the prognostic ability of the anti-CCP test. The presence of these antibodies early in disease development opens a window of opportunity for early custom-tailored treatment of RA. Finally, we will review the effect of disease treatment on anti-CCP levels and briefly go into the putative functional role of these antibodies in the chronic aspects of RA. The autoantibody system most specific for RA known to date is that directed to citrullinated antigens. The citrulline moiety, which is the essential part of the antigenic determinant in these antigens, is post-translationally generated by peptidylarginine deiminases (PAD; EC 3.5.3.15) [9]. RA autoantibodies against citrullinated antigens have been detected and used for diagnostic purposes for many decades via the well-known antiperinuclear factor (APF) [10] and antikeratin antibody (AKA) tests [11]. Supported by the fact that APF and AKA share many features, as reviewed previously [12], and are reactive with native filaggrin, these autoantibodies are now designated as antifilaggrin antibodies (AFA) [13]. Using the laborious and inconvenient immunofluorescence assay, roughly 50% of RA sera can be scored AFA-positive. A key finding was the discovery that the reactivity of these AFA was completely dependent on the presence of citrulline residues (present in mature filaggrin but not in profilaggrin) [14, 15]. Since then, two approaches for detecting autoantibodies to citrullinated epitopes have been taken: a protein-based and a peptide-based approach. Screening for citrulline-specific RA reactivity has been performed with several proteins, including both purified naturally occurring citrullinated proteins and in vitro-citrullinated proteins. For these purposes, mainly filaggrin, fibrinogen and myelin basic protein have been used. Although most of these proteins are arginine-rich, there is obviously a limit to the number of citrullinated epitopes associated with a certain protein. A complication of the use of natural antigens is that it is difficult to obtain reasonable amounts in sufficient purity in a reproducible way. Batch-to-batch variation also compromises standardization when in vitro citrullination is used to generate the antigen. Insufficient purity of the antigen lowers the specificity of the test because reactivities directed to other components (e.g. the PAD enzyme, the non-citrullinated part of the antigen, other contaminants) may be detected as well. The use of proper (non-citrullinated) controls is therefore very important, as
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Klareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Syversen, S. W., Gaarder, P. I., Goll, G. L., Ødegård, S., Haavardsholm, E. A., Mowinckel, P., van der Heijde, D., Landewé, R., & Kvien, T. K. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068247 · Cited by 319
van der Pouw Kraan, T. C. T. M., Wijbrandts, C. A., van Baarsen, L. G. M., Voskuyl, A. E., Rustenburg, F., Baggen, J. M., Ibrahim, S. M., Fero, M., Dijkmans, B. A. C., Tak, P. P., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063412 · Cited by 313
Role of Epigenetics in Inflammation-Associated diseases
Shanmugam, M. K., & Sethi, G. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_27 · Cited by 141
Eggleton, P., Nissim, A., Ryan, B. J., Whiteman, M., & Winyard, P. G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.006 · Cited by 37
Metadata
- Authors
- Zendman, A. J. W., van Venrooij, W. J., & Pruijn, G. J. M.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-27
- Volume
- 45
- Issue
- 1
- Pages
- 20-25
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2113877029
- Cited by
- 162
- References
- 0
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/kei111
- The paper
- Zendman, A. J. W., van Venrooij, W. J., & Pruijn, G. J. M. (2006). Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/kei111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.